May 7 |
Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting
|
Apr 22 |
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
|
Mar 26 |
Neurogene Stock: Gene Therapy Specialist May Break Chain Of Failed Mergers
|
Mar 20 |
Neurogene Inc (NGNE) Reports Financial Results for Q4 and Full Year 2023
|
Mar 19 |
With 32% ownership, Neurogene Inc. (NASDAQ:NGNE) has piqued the interest of institutional investors
|
Mar 18 |
Neoleukin Therapeutics reports Q4 results
|
Mar 18 |
Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates
|
Mar 4 |
Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial
|
Feb 29 |
Neurogene to Participate in Upcoming Investor Conferences
|
Jan 16 |
Neurogene names Julie Jordan as chief medical officer
|